Table 1.
Main characteristics of the studies included in the meta-analysis.
| Included studies | studies design | Treatment group | Control group | Sample size | Age, years | Sex (male/female) | Line | |
|---|---|---|---|---|---|---|---|---|
| 1 | Adhoute 2022 | Retrospective multicenter study | Regorafenib | Cabozantinib | 58:28 | 68:68 | 53/5:24/4 | Second-line therapy |
| 2 | Bang 2021 | Retrospective study | Regorafenib | physician’s choice | 99:99 | / | / | Second-line therapy |
| 3 | Bruix 2017 | RCT | Regorafenib | Placebo | 379:194 | 64:62 | 333/46:171/23 | Second-line therapy |
| 4 | Finn 2018 | RCT | Regorafenib | Placebo | 379:194 | 64:62 | 333/46:171/23 | Second-line therapy |
| 5 | Casadei-gardini 2021 | Retrospective Study | Regorafenib | Cabozantinb | 278:331 | / | 222/46:264/67 | Second-line therapy |
| 6 | Choi 2020 | Retrospective study | Regorafenib | Nivolumab | 223:150 | 58.5 ± 9.4:56.9 ± 10 | 202/21:125/25 | Second-line therapy |
| 7 | Iavarone 2021 | Retrospective Study | Regorafenib | Best supportive care (BSC) | 36:45 | 60:61 | 27/9:38/7 | Second-line therapy |
| 8 | Kuo 2021 | Retrospective study | Regorafenib | Nivolumab | 58:32 | 63.4 ± 10.7:62.2 ± 10.1 | 44/14:23/9 | Second-line therapy |
| 9 | Lee 2020 | Retrospective cohort study | Regorafenib | Nivolumab | 102:48:00 | 62:61 | 83/54:39/9 | Second-line therapy |
| 10 | Lee 2024 | Retrospective cohort study | Regorafenib | Nivolumab | 137:52:00 | 63:59:00 | 120/17:45/7 | Second-line therapy |